Contact

EN

中文 English

中文 English

Search

Search

Hankang Portfolio | Hankang Capital's Early Conviction in Oral Macrocyclic Peptides Validated by PepStar's $1.275 Billion Transaction with Gilead

Hankang Portfolio | SciBrunch Therapeutics Enters into Exclusive Global License Agreement with MSD for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor

Hankang Portfolio | InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines

Hankang Portfolio | AusperBio Announces Completion of $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies

Hankang Portfolio | Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World’s First Approved 4-1BB-Targeting Therapy

Hankang Portfolio | Abbisko Therapeutics Announces IND Clearance from the NMPA for Oral Small Molecule pan-KRAS Inhibitor ABSK211

For any investor inquiries, please feel free to contact us.

Want to learn more about technical information?
Hongkong Shanghai Beijing

Copyright 2026 © Hankang All Rights Reserved.